The Role of Combination Therapy or Co-Formulation Products in the Treatment of Type 2 Diabetes
Activity Preview
This article provides information about the use of combination therapy or co-formulation products in
Learning Objectives
At the completion of this activity, the pharmacist will be able to:
1. List five co-formulation products used to treat type 2 diabetes.
2. List two advantages and two disadvantages to using co-formulation products.
3. Describe the evidence that supports a physiologic approach to treating type 2 diabetes using combination therapy.
4. Describe the physiologic actions of the different classes of medications to treat type 2 diabetes.
5. Name two drug combinations that should not be used to treat type 2 diabetes because of similar mechanisms of action.
6. Identify when combination therapy is recommended in the 2018 ADA Glycemic Control Algorithm and the 2018 AACE Glycemic Control Algorithm.
7. List possible side effects or safety considerations of different medications used to treat type 2 diabetes.
Activity type: Knowledge-based
Target Audience: Pharmacists
Learning level: 1
Accreditation Information
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours of CPE credit (0.20 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-18-246-H01-P.
To obtain credit for The Role of Combination Therapy or Co-Formulation Products in the Treatment of Type 2 Diabetes complete the assessment with a grade of 70% or better, complete the evaluation, and then claim credit. Participants need to have a valid pharmacist.com username and password to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.
APhA's continuing pharmacy education policy allows two opportunities to successfully complete the continuing pharmacy education assessment. Please note that the questions may not appear in the same order as printed and only two attempts to pass the assessment will be granted. The current policy of the APhA Education Department is to not release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.
Initial release date: August 1, 2018
Expiration date: August 1, 2021 - NO CREDIT GRANTED AFTER THIS DATE
Development
The Role of Combination Therapy or Co-Formulation Products in the Treatment of Type 2 Diabetes is a home-study continuing education activity for pharmacists and pharmacy technicians developed by the American Pharmacists Association.
Advisory Board
Jennifer M. Trujillo, PharmD, BCPS, FCCP, CDE, BC-ADM
Associate Professor, Department of Clinical Pharmacy
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, CO
Stuart T. Haines PharmD, BCPS
Professor and Director, Pharmacy Professional Development
University of Mississippi School of Pharmacy
Jackson, Mississippi
Disclosures
Jennifer M. Trujillo, PharmD, BCPS, FCCP, CDE, BC-ADM, declares that she is a paid consultant for Sanofi. Stuart T. Haines, PharmD, BCPS, and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For complete staff disclosures, please see the Education and Accreditation Information section at www.pharmacist.com/apha-disclosures.
Fee
There is no fee associated with this activity for members of the American Pharmacists Association. There is a $25 fee for nonmembers.
System Requirements
Computer and internet access are required to complete this activity. Please visit our website and view the Technology System Requirements to have a positive learning experience.